BostonGene’s Post

Lung cancer is the leading cause of cancer-related deaths worldwide. As we observe #WorldLungCancerDay, we continue to press forward with research that could improve outcomes for patients with lung cancer and other solid tumors. #LungCancerAwareness #biotechnology #CancerResearch #jsmePPF

Are you involved in cancer care? If so you are involved in biomarker testing; These 2 infographic posters can give you easily accessible, best practice information about precision oncology biomarker testing. The first covers how to address Pre-analytical Challenges,: https://ow.ly/4Brk50T31JM The second covers how to Optimise Samples: https://ow.ly/QVEC50T31JN This educational programme is supported by an Independent Educational Grant from Bayer. #MedEd #MedicalEducation #precisionMedixine#PrecisionMedicine #precisionOncology #biomarker #LungCancer #ProstateCancer #GastricCancer

Check out GTC's new publication in ImmunoMedicine: The use of transcriptomic data in developing biomarkers in breast cancer https://lnkd.in/dEuBkdRi #GenomicTestingCooperative #TranscriptomicResearch #PrecisionMedicine #NGSSequencing #BiomarkerDiscovery

Resolving Diagnostic Uncertainty - Learn more about Interpace Diagnostics' novel molecular diagnostic tests for thyroid and pancreatic cancer at FSP. https://lnkd.in/gNytsCxt #thyroidcancer #pancreaticcancer #molecular 

Advancements in isothermal amplification technologies are fueling new diagnostic and clinical approaches for pathogen detection and cancer research. This one was a bear to write but really proud of how it turned out. Download and read to learn more! https://lnkd.in/gaRUhBYJ

Exciting news! Our Business Development team is in Charlotte, North Carolina this week end to attend the AACR special conference on bladder cancer. If you're attending as well, be sure to stop by our booth to learn about how our cutting-edge #MIBC and #NMIBC models for preclinical oncology drug development. See you there! Discover more https://hubs.ly/Q02xFVXb0 #AACR2024 #BladderCancer #OncologyResearch #PreclinicalDrugDevelopment.

The final version of the paper validating SeqOne Genomics HRD biomarker for ovarian cancer patients is available online https://lnkd.in/gFa3gyn4 with key figures indicating that efficiency of PARPi is the same for HRD+ patients when using the reference test or the newly developed one .

Targeted cancer therapies are more diverse than ever, including innovations like Designed Ankyrin Repeat Proteins (DARPins). Learn how Molecular Partners is using DARPins to address medical challenges beyond traditional treatments: https://lnkd.in/dXT9fhgW This article is part of our 25th-anniversary series, launched in 2023. If you are interested in shaping and sponsoring a story on the diversity of our industry too, reach out to us. #CancerResearch #SwissBiotech #TargetedTherapies #DARPins #HealthcareInnovation

📢 This morning at #ESMO24, our CEO, Marc Stapley, spoke with BiotechTV to discuss groundbreaking new data supporting our plan to expand the use of the #DecipherProstate test to metastatic prostate cancer patients. This test, already guiding care for localized prostate cancer, now shows potential in predicting which patients could benefit from adding chemotherapy to androgen deprivation therapy, thanks to insights from an analysis of Decipher Prostate in a phase 3 trial of the multi-center, randomized STAMPEDE clinical trial. These findings are a significant step forward in precision medicine, enabling urologists and oncologists to tailor treatment more effectively with the potential to improve patient outcomes. Learn more about how we're transforming prostate cancer care with our innovative diagnostics. 👉 Watch the full interview with Marc Stapley on BioTech TV: https://lnkd.in/gNAeST4V #ProstateCancer #STAMPEDEStudy #PrecisionMedicine #Oncology #Urology #ProstateHealth #Veracyte #BioTechTV #CancerDiagnostics

#ONSCongress Dana-Farber Cancer Institute join me at 3:00 today for my presentation “Implementing high-fidelity simulation to enhance bispecific antibody induced cytokines release syndrome education.”